Evidence map›Paper›PMID 37257735›Full record

ReviewAnalytical biochemistry2023

Research progress in methods for detecting neutralizing antibodies against SARS-CoV-2.

Chunxia Chen, Jiahui Liang, Hangzhan Hu, Xiaoquan Li, Li Wang, Zhizeng Wang

Open access · greenAbstract readReview
In one paragraph

Review in Analytical biochemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Serum AZD7442 (tixagevimab-cilgavimab) concentrations andClinical & translational immunology · 2024
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chunxia ChenJoint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, Henan University, Kaifeng, 475004, China.
Jiahui LiangJoint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, Henan University, Kaifeng, 475004, China.
Hangzhan HuJoint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, Henan University, Kaifeng, 475004, China; Heze Municipal Hospital, Heze, 274000, China.
Xiaoquan LiHeze Municipal Hospital, Heze, 274000, China.
Li WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Henan University, Kaifeng, 475004, China. Electronic address: wangli851217@163.com.
Zhizeng WangJoint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, Henan University, Kaifeng, 475004, China; Center of Smart Laboratory and Molecular Medicine, School of Medicine, Chongqing University, Chongqing, 400044, China. Electronic address: wzhzeng@126.com.
First Affiliated Hospital of Henan University · CNHeze Municipal Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of SARS-CoV-2 has seriously affected the lives of people worldwide. Clarifying the attenuation rule of SARS-CoV-2 neutralizing antibody (NAb) in vivo is the key to prevent reinfection and recurrence of virus. Currently, the commonly used methods for detecting NAb include virus neutralization tests, pseudovirus neutralization assays, lateral flow immunochromatography and enzyme-linked immunosorbent assays. The detection of NAb not only can be used to evaluate the level of immunity after vaccination or infection but also can provide important theoretical support for virus reinfection, recurrence and vaccine iteration. In this research, the related technologies of SARS-CoV-2 NAb detection were reviewed, aiming to provide better research ideas for SARS-CoV-2 epidemic prevention and control.

Indexed as

Antibodies, NeutralizingCOVID-19Antibodies, ViralHumansReinfectionSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralDetection methodLateral flowNeutralizing antibodySARS-CoV-2

Identifiers

PMID37257735
PMCPMC10226777
OpenAlexW4378639320

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.